Inflexion, a leading European mid market private equity firm, is pleased to announce that it has agreed to acquire Primed Group (“Primed”), a specialist German provider of high-quality medical consumables and sterilisation services. The business is being acquired from Paragon Partners, a DACH-focused private equity firm. The investment is being made by Inflexion's Buyout Fund VI and represents Inflexion's sixth investment in the DACH region.
Founded in 1946 and headquartered in Halberstadt, Germany, Primed designs, manufactures and distributes certified single-use medical consumables. The business employs more than 450 people across a vertically integrated platform spanning the full value chain, from compounding to final sterile product. Its MDR-certified products are used in over 70 countries, supplying hospitals and medical care facilities. Primed also operates HA2, one of Europe's largest medical sterilisation platforms.
The global market for single-use medical consumables is large and growing, giving Primed a strong platform to expand further in Germany and internationally. Under Inflexion's ownership, Primed will continue to invest in its core product range, accelerate product development and drive further growth in its sterilisation business. Inflexion will support management in accelerating international expansion through targeted acquisitions and investments in commercial capabilities, strengthening Primed's direct access to customers in key markets. The investment reflects Inflexion's commitment to partnering with leading local healthcare businesses and supporting their long-term success.
Inflexion has partnered with healthcare leaders Wolfgang Suessle and Justin Barnes to complete the acquisition, with both joining Primed's Board of Directors. Wolfgang brings more than 25 years of healthcare experience, including 15 years as CEO and President of Lohmann & Rauscher. Justin has over 25 years’ experience in the medical device sector, having co-founded several businesses and held multiple senior leadership roles including CEO of 30 Technology and Non-Executive Director of Rayner. Together, they bring complementary expertise and a strong track record of scaling healthcare businesses to help execute Primed's growth strategy.
This is Inflexion's third healthcare investment in the region, following its minority investment in Proteros and its investment in Tierarzt Plus Partner.The acquisition further strengthens Inflexion’s presence in DACH, following the launch of Mittelstands-Assekuranz-Partner (‘MAP’), the carve out of Finanzen.net and the investment in dss+.
Primed has built a strong reputation through its high-quality product portfolio, integrated business model and long-standing customer relationships. We are delighted to be partnering with the team to support the next phase of the company's growth.
Primed has significant opportunities to build on its leading market position. Drawing on our experience helping healthcare businesses scale internationally through organic growth, strategic acquisitions, commercial excellence and new product development, we look forward to partnering with the management team as they expand the business and extend its global reach.
Primed is an outstanding example of the innovative, internationally competitive businesses we are looking to partner with in Germany. We look forward to supporting the management team as they build on the company's strong domestic foundations and continue to expand internationally.
We are delighted to welcome Inflexion as our new partner. They share our long-term vision for Primed and HA2. and bring significant experience in supporting ambitious businesses through their next phase of growth. Together, we look forward to building on Primed's strong German heritage as we continue to expand internationally, invest in innovation and deliver high-quality products to hospitals and medical facilities worldwide.
The transaction is subject to customary regulatory approvals.
Contact us
Please contact us if you have any media enquiries
